DermTech Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Algemeen directeur
n/a
Totale compensatie
| Percentage CEO-salaris | n/a |
| Dienstverband CEO | no data |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 2.3yrs |
| Gemiddelde ambtstermijn bestuur | 5.3yrs |
Recente managementupdates
Recent updates
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%
May 21
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02CEO
DermTech heeft geen CEO, of we hebben geen gegevens over hen.
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | no data | US$480.83k | geen gegevens | |
| Head of Finance | no data | geen gegevens | geen gegevens | |
| Senior Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Compliance Officer | 2.3yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 3.4yrs | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
Ervaren management: Het managementteam van DMTK.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Independent Director | 5.3yrs | US$149.64k | 0.28% $ 0.1 | |
| Independent Director | 2.3yrs | US$136.64k | 0.094% $ 0.03 | |
| Independent Chairman of the Board | 8.3yrs | US$188.64k | 0.35% $ 0.1 | |
| Independent Director | 2.3yrs | US$139.64k | 0.081% $ 0.03 | |
| Independent Director | 5.3yrs | US$156.64k | 0.20% $ 0.07 | |
| Member of Clinical Advisory Board | 7.1yrs | geen gegevens | geen gegevens | |
| Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 3.1yrs | US$134.64k | 0.092% $ 0.03 | |
| Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Clinical Advisory Board | 5.8yrs | geen gegevens | geen gegevens | |
| Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Clinical Advisory Board | no data | geen gegevens | geen gegevens |
5.3yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DMTK.Q wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).